ViewRay Finalizes Order for MR Image-Guided Radiation Therapy System at University Hospital Zurich
Oncologists at Leading Swiss Hospital Select MRIdian Linac as Preferred Technology In Competitive European Tender
Mar 14, 2018, 08:30 ET
CLEVELAND, March 14, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today an order for the company's MRIdian® MR image-guided linac at the University Hospital Zurich (USZ) in Zurich, Switzerland. The order formalizes the previously announced tender award from the Swiss National R'Equip programme. Once commissioned, the USZ MRIdian system will be the first in Switzerland, and among the first MR-guided linac systems in Europe to treat patients.
USZ is one of the largest and most important teaching hospitals in Europe, renowned for its health care and research achievements. The USZ tender award process included a competitive and comprehensive technology review. According to the tender award, MRIdian was selected as the "only device that met all the latest technological requirements" and "could fit into the existing premises as a replacement device," highlighting the system's unique capabilities and ability to fit into standard radiotherapy vaults.
"MRIdian brings a level of real-time visibility and treatment adaptation that is not possible using standard radiation therapy technology," said Professor Matthias Guckenberger, M.D., chairman of the Department of Radiation Oncology at USZ. "We look forward to expanding our offerings to include MRIdian's advanced imaging and delivery capabilities to enhance the level of care we bring to our patients."
Unlike conventional radiotherapy, the MRIdian system provides diagnostic-quality MR visualization of soft-tissue targets and surrounding organs. This technological advance enables daily on-table treatment plan adaptation to quickly and dynamically adjust for subtle anatomical changes that may occur, both during treatment delivery and throughout the course of treatment. Combined, these capabilities provide the potential for clinicians to improve targeting precision and thus deliver higher, and potentially more effective, radiation doses.
A key focus of USZ's MRIdian MR image-guided radiation therapy program will be MR-guided adaptive radiotherapy, particularly stereotactic radiosurgery for treating oligo-metastatic disease, head and neck, and lung cancer. The MRIdian Linac will also be utilized as part of the hospital's Radiomics biomarker research for response prediction and assessment, in collaboration with the Swiss Federal Institute of Technology in Zurich (ETH), which is ranked among the top universities in the world.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges including beam distortion, skin toxicity, and other safety concerns, which may potentially occur when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include the ability to deliver improved dose delivery, minimized toxicity sparing and minimizing dose to organs and critical structures near cancerous tumors, significantly reduced exposure to surrounding healthy tissues, reduced skin toxicity and safety concerns and improved patient outcomes. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
SOURCE ViewRay, Inc.